| scholarly article | Q13442814 |
| P50 | author | Won Ho Kim | Q63809158 |
| Nayoung Kim | Q40152658 | ||
| Byong Duk Ye | Q42748253 | ||
| P2093 | author name string | Hyun Soo Kim | |
| Yu Kyung Cho | |||
| Seong Ran Jeon | |||
| Yoon Tae Jeen | |||
| Tae Oh Kim | |||
| Dong Soo Han | |||
| Young Ho Kim | |||
| Sun Young Lee | |||
| You Sun Kim | |||
| Byung Ik Jang | |||
| Hyun Joo Song | |||
| Joo Sung Kim | |||
| Kang Moon Lee | |||
| Chang Kyun Lee | |||
| Sung Jae Shin | |||
| Ji Won Kim | |||
| Dong Il Park | |||
| Won Ho Kim | |||
| Hyo Jong Kim | |||
| Ja Seol Koo | |||
| Chang Hwan Choi | |||
| Sae Kyung Chang | |||
| Jae Myung Cha | |||
| Tae Joo Jeon | |||
| Jae Hak Kim | |||
| Young Sook Park | |||
| Bo In Lee | |||
| Eun Soo Kim | |||
| Soo Jung Park | |||
| IBD Study Group of the Korean Association for the Study of the Intestinal Diseases | |||
| In Do Song | |||
| Jong Pil Im | |||
| Suk Kyun Yang | |||
| Sung Ae Jung | |||
| P2860 | cites work | A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 |
| Infliximab, azathioprine, or combination therapy for Crohn's disease | Q56988763 | ||
| Risk and clinical characteristics of lymphoma in Korean patients with inflammatory bowel diseases: a multicenter study | Q57221578 | ||
| [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience] | Q57224134 | ||
| A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease | Q74460284 | ||
| Infliximab in treatment of Crohn's disease: the Milan experience | Q74496964 | ||
| Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study | Q81734312 | ||
| Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population | Q83463037 | ||
| Safety of infliximab in Crohn's disease: a large single-center experience | Q85043173 | ||
| Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy | Q27005716 | ||
| Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 | ||
| Infliximab maintenance therapy for fistulizing Crohn's disease | Q28246982 | ||
| Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 | ||
| Construction and initial characterization of a mouse-human chimeric anti-TNF antibody | Q34060890 | ||
| Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry | Q34065405 | ||
| Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). | Q34081925 | ||
| The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? | Q34147687 | ||
| Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial | Q34156631 | ||
| Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial | Q34574245 | ||
| Active pulmonary tuberculosis and latent tuberculosis infection among homeless people in Seoul, South Korea: a cross-sectional study | Q34893260 | ||
| Management of Crohn's disease in adults. | Q34931424 | ||
| Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression | Q36671830 | ||
| Prevalence of Latent Tuberculosis Infection among Health Care Workers in South Korea: A Multicenter Study. | Q37090046 | ||
| Etiology of perianal Crohn's disease: role of genetic, microbiological, and immunological factors | Q37564302 | ||
| Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy | Q37606758 | ||
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis | Q37814539 | ||
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management | Q37814541 | ||
| Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis | Q37853360 | ||
| Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis | Q37853365 | ||
| Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. | Q37925683 | ||
| Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease | Q37937180 | ||
| Treat to target: a proposed new paradigm for the management of Crohn's disease | Q38137614 | ||
| Future directions in inflammatory bowel disease management | Q38205305 | ||
| Classification of inflammatory bowel disease | Q44185737 | ||
| Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea | Q45387141 | ||
| Trends in tuberculosis--United States, 2012. | Q45824432 | ||
| Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. | Q45966647 | ||
| Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate | Q47784405 | ||
| Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial | Q49167560 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P921 | main subject | Crohn's disease | Q1472 |
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 1376-1385 | |
| P577 | publication date | 2016-11-01 | |
| P1433 | published in | Yonsei Medical Journal | Q8055114 |
| P1476 | title | Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study | |
| P478 | volume | 57 |
| Q54919523 | Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn's disease. |
| Q54940383 | Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. |
| Q38750548 | Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. |
| Q57074034 | Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database |
| Q99234081 | Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease |
Search more.